BTIG Research Analysts Give Myriad Genetics (MYGN) a $44.00 Price Target

Myriad Genetics (NASDAQ:MYGN) received a $44.00 target price from stock analysts at BTIG Research in a note issued to investors on Wednesday. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price target points to a potential upside of 34.89% from the stock’s previous close.

A number of other research analysts also recently commented on the company. Leerink Swann increased their target price on Myriad Genetics from $33.00 to $35.00 and gave the company a “market perform” rating in a research report on Wednesday. Morgan Stanley increased their target price on Myriad Genetics from $26.00 to $28.00 and gave the company an “underweight” rating in a research report on Wednesday. Goldman Sachs Group assumed coverage on Myriad Genetics in a research report on Monday, January 29th. They set a “sell” rating and a $32.00 target price for the company. Barclays increased their target price on Myriad Genetics from $30.00 to $35.00 and gave the company an “equal weight” rating in a research report on Monday, January 22nd. Finally, BidaskClub upgraded Myriad Genetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 20th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $31.42.

Myriad Genetics (MYGN) traded down $1.21 during mid-day trading on Wednesday, reaching $32.62. The company’s stock had a trading volume of 1,020,943 shares, compared to its average volume of 788,239. Myriad Genetics has a 1-year low of $15.71 and a 1-year high of $41.57. The company has a quick ratio of 2.06, a current ratio of 2.34 and a debt-to-equity ratio of 0.09. The company has a market cap of $2,479.51, a P/E ratio of 17.63, a price-to-earnings-growth ratio of 2.26 and a beta of 0.32.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $0.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.07. The business had revenue of $194.00 million during the quarter, compared to the consensus estimate of $188.72 million. Myriad Genetics had a return on equity of 9.94% and a net margin of 16.67%. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.26 EPS. equities analysts predict that Myriad Genetics will post 1.06 EPS for the current fiscal year.

In related news, Director Walter Phd Gilbert sold 7,500 shares of the stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $33.19, for a total transaction of $248,925.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Heinrich Dreismann sold 6,000 shares of the stock in a transaction on Monday, December 11th. The shares were sold at an average price of $33.50, for a total value of $201,000.00. Following the sale, the director now owns 33,743 shares in the company, valued at approximately $1,130,390.50. The disclosure for this sale can be found here. Insiders have sold a total of 71,064 shares of company stock worth $2,679,097 in the last 90 days. 6.70% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. increased its stake in Myriad Genetics by 1,067.4% in the third quarter. Meeder Asset Management Inc. now owns 3,292 shares of the company’s stock worth $119,000 after purchasing an additional 3,010 shares during the period. LS Investment Advisors LLC increased its stake in Myriad Genetics by 88.5% in the fourth quarter. LS Investment Advisors LLC now owns 4,791 shares of the company’s stock worth $165,000 after purchasing an additional 2,250 shares during the period. Tiedemann Wealth Management LLC increased its stake in Myriad Genetics by 67.0% in the third quarter. Tiedemann Wealth Management LLC now owns 13,650 shares of the company’s stock worth $185,000 after purchasing an additional 5,475 shares during the period. Commonwealth Equity Services Inc purchased a new stake in Myriad Genetics in the third quarter worth $202,000. Finally, Teacher Retirement System of Texas purchased a new stake in Myriad Genetics in the third quarter worth $204,000.

ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/08/btig-research-analysts-give-myriad-genetics-mygn-a-44-00-price-target.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply